Overview

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the superiority of Respimat®.

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Tiotropium Bromide